The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.